|
|
|
| |
|
|
| |
The latest oncology news from News Medical |
|
|
|
 | | |  Metabolic rewiring could help CAR-T cells fight solid tumors This review explains how glucose scarcity, lipid disruption, amino acid deprivation, and toxic metabolites weaken CAR-T cells inside solid tumors. It highlights metabolic reprogramming as a promising strategy to improve CAR-T cell persistence, adaptability, and anti-tumor function. | | | | |  Scientists redesign CAR-T cells to fight more than cancer This review examines how CAR-T cell therapy is expanding beyond blood cancers into solid tumors, autoimmune diseases, chronic viral infections, and next-generation immune-cell platforms. It highlights promising engineering advances, including universal CAR-T cells, in vivo delivery, CAR-NK cells, and safety switches, while emphasizing unresolved challenges in durability, safety, scalability, and global access. | | | | |  How fast your face ages may predict cancer survival outcomes The study links facial aging rates to cancer outcomes, suggesting a new prognostic tool that could personalize treatment and enhance patient survival. | |
|
|
|  | | | | |  From killers to strategists: CAR T cells enter their multifunctional era A review of 1,801 registered CAR T clinical trials shows that multifunctional designs now account for 533 trials and 33% of new CAR T products submitted for clinical testing in 2025. The field is shifting toward multitargeted, safety-controlled, cytokine-secreting, and checkpoint-modulating CAR T cells, but manufacturing, regulation, and limited clinical outcome data remain key barriers. | |  | | | | |  Single-cell sequencing reveals why some CAR-T therapies succeed while others fail Single-cell RNA sequencing is giving researchers a clearer view of why some CAR-T cells persist, expand, kill tumors effectively, or become exhausted. The review synthesizes 44 clinical scRNA-seq studies involving 500 patients and highlights how exhaustion, memory, cytotoxicity, clonal diversity, and metabolism may shape CAR-T responses. | | | | | | |  Rising bowel and ovarian cancer rates in younger adults raise new concerns Cases of several cancers are rising in England among both younger and older adults, but rates of bowel and ovarian cancer are rising only among younger adults (under 50s), finds research published in the open access journal BMJ Oncology. | |
|
|
| | | |  A new research paper was published in Volume 17 of Oncotarget on April 28, 2026, titled "Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis from 1975 to 2023." | | | | |  The National Comprehensive Cancer Network® (NCCN®)-an alliance of leading cancer centers-has published a new book explaining the latest evidence and expert recommendations around prostate cancer screening. | | | | |  Diaceutics, the intelligence and engagement company unlocking the full potential of diagnostic-driven therapies, has released new research revealing a critical shift in precision medicine. Despite major advances in biomarker testing, nearly two-thirds of eligible patients with advanced non-small cell lung cancer (aNSCLC) in the US are still not receiving the most appropriate treatment | | | | |  Scientists at The Wistar Institute and clinical researchers from ChristianaCare's Helen F. Graham Cancer Center & Research Institute have discovered a vulnerability in pancreatic cancer that could be targeted as a potential therapy. | | | | |  Immunotherapy has become a standard of care in treating high-risk, early-stage breast cancers, yet it has had limited success in shrinking tumors. | | | | |  A new national survey reveals many women are unsure about when to start mammogram screening for breast cancer and believe they should start later than doctors recommend. | | | | |  This study analyzes BRCA testing patterns in U.S. breast cancer patients, highlighting barriers and disparities in access to genetic testing and precision care. | | | | |  Brain tumors cannot always be successfully treated with conventional therapies. A team from Empa and the hospital network HOCH Health Ostschweiz is therefore developing nanozymes that can attack cancer cells directly in the brain during tumor surgery. | | | | |  The Alliance for Clinical Trials in Oncology is now enrolling patients in the ASPIRE trial (A032302)-a large-scale, phase III clinical study investigating whether adding chemotherapy to current standard treatments extends survival for men with advanced prostate cancer. | |
|
|
|
|
|
|
|
